<?xml version="1.0" encoding="UTF-8"?>
<ref id="j_jtim-2019-0012_ref_022">
 <label>22</label>
 <element-citation publication-type="journal">
  <name>
   <surname>Koshimichi</surname>
   <given-names>H</given-names>
  </name>
  <name>
   <surname>Ishibashi</surname>
   <given-names>T</given-names>
  </name>
  <name>
   <surname>Kawaguchi</surname>
   <given-names>N</given-names>
  </name>
  <name>
   <surname>Sato</surname>
   <given-names>C</given-names>
  </name>
  <name>
   <surname>Kawasaki</surname>
   <given-names>A</given-names>
  </name>
  <name>
   <surname>Wajima</surname>
   <given-names>T</given-names>
  </name>
  <article-title>Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings</article-title>
  <source>Clin Drug Investig</source>
  <year>2018</year>
  <volume>38</volume>
  <fpage>1189</fpage>
  <comment>â€“</comment>
  <lpage>96</lpage>
 </element-citation>
</ref>
